Read Our Latest Issue The Food and Drug Administration, Sarepta and the case of the missing drug data The Food and Drug Administration is seldom accused of being too transparent. But in late September it looked like the agency had overshared. In an attempt to achieve the "greatest level of transparency," the FDA caused the stock prices of four biotech companies to hemorrhage. Jittery traders, sifting through scraps of context-free information provided by the agency, dumped their drug stocks, triggering a brief but brutal plunge. This is a preview. Make a selection below to access this issue.Already have access? . Having trouble accessing this article? Please visit our page for more information Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners. Follow us Scientific american arabic (c) 2021 Scientific American, a Division of Springer Nature America, Inc. All Rights Reserved. Support our award-winning coverage of advances in science & technology. Already a subscriber? Subscribers get more award-winning coverage of advances in science & technology.